Erratum: First-in-class pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights
- PMID: 35229349
- DOI: 10.1002/ardp.202270007
Erratum: First-in-class pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights
Erratum for
-
First-in-class pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights.Arch Pharm (Weinheim). 2022 Apr;355(4):e2100440. doi: 10.1002/ardp.202100440. Epub 2022 Feb 1. Arch Pharm (Weinheim). 2022. PMID: 35106845
Publication types
LinkOut - more resources
Full Text Sources
